Analysts at the major investment banks are generally in agreement with Sanofi CEO Paul Hudson’s assessment of the firm’s Consumer Healthcare (CHC) separation plan as a “win win.”
“Our early take on these strategic actions is that the separation of CHC is the right thing to do strategically,” said Barclays’ Emily Field, while HSBC’s Rajesh Kumar and Jefferies’ Peter Welford separately noted the decision had been eagerly